БУЛТОН Крейг (GB),БЮРТЕН Паскаль (CH),ДАВИД Оливье (CH),ДЕ-ВЕРА Ана (CH),ДЮМОРТЬЕ Томас (CH),ХАНТ Айрин (CH),ШМОУДЕР Роберт (US)
申请号：
RU2012117563/15
公开号：
RU2012117563A
申请日:
2010.09.20
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method of treating an inflammatory or autoimmune disease or disorder in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of an S1P receptor modulator or agonist such that side effects that may be associated with the administration of said S1P receptor modulator or agonist, are controlled, limited, reduced or eliminated, the method comprising the steps of: i) monitoring the patient for a certain period time after the first administration of the indicated modulator or agonist of the S1P receptor, wherein said monitoring of the patient includes one or more steps: a) monitoring of infections or infestations, for example, viral infections, during the time of administration of the specified modulator or agonist of the S1p receptor, b) performing ophthalmic examination, ii) optionally discontinuing the administration of the indicated S1P receptor modulator or agonist and / or modifying the treatment regimen. 2. A method for controlling, reducing or eliminating possible side effects associated with treating a patient with an inflammatory or autoimmune disease or with a disorder with a S1P modulator or receptor agonist, comprising administering to the patient a therapeutically effective amount of said S1P receptor modulator or agonist, said method comprising one or more stages: a) monitoring infections or infestations, for example, viral infections, b) performing an ophthalmological examination, ii) optionally terminated the introduction of the specified modulator or agonist of the S1P receptor and / or modification1. Способ лечения воспалительного или аутоиммунного заболевания или расстройства у пациента, нуждающегося в таком лечении, включающий введение указанному пациенту терапевтически эффективного количества модулятора или агониста рецептора S1P таким образом, что побочные проявления, которые могут быть ассоциированы с введением указанного модулятора или агониста рецептора S1P, находятся под контролем,
